Patents Examined by Rei Tsang Shiao
  • Patent number: 11173137
    Abstract: Provided herein are small-molecules for use in modulating chloride ion channel (CLC) activity, particularly the activity of CLC-2, to elucidate the role of CLC-2 in disorders associated with CLC-2 malfunction, and to identify therapeutic leads for their treatment. Compositions and methods for modulating CLC activity are also provided. In certain aspects, the subject compounds and compositions are useful for imaging or channel pull-down studies.
    Type: Grant
    Filed: June 21, 2019
    Date of Patent: November 16, 2021
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Anna K. Koster, Justin Du Bois, Merritt C. Maduke
  • Patent number: 11172673
    Abstract: Disclosed are compositions and methods for slowing, preventing, or reversing platelet damage, particularly as may occur during blood banking or during refrigeration of platelets. The composition may include one or more of a RAC inhibitor, a CDC42 inhibitor, a RHOA inhibitor, or a combination thereof. The compositions may further include a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: July 20, 2018
    Date of Patent: November 16, 2021
    Assignees: CHILDREN'S HOSPITAL MEDICAL CENTER, UNIVERSITY OF CINCINNATI
    Inventors: Yi Zheng, Jose Cancelas
  • Patent number: 11166928
    Abstract: The invention relates to a compound for use in a method of treatment or prevention of migraine and/or symptoms thereof. The compound is selected from beta-hydroxybutyric acid (?HB) or a pharmaceutically acceptable salt thereof, acetoacetate (AcAc) or a pharmaceutically acceptable salt thereof, a metabolic precursor of ?HB or AcAc 1,3-butanedio and a compound comprising an acetoacetyl- or 3-hydroxybutyrate moiety. The invention further relates to a pharmaceutical composition comprising ?HB, AcAc or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: November 9, 2021
    Inventors: Elena Gross, Dirk Fischer
  • Patent number: 11147817
    Abstract: The present invention relates to pharmaceutical composition comprising pemetrexed, a ready to use injection comprising pemetrexed. Liquid composition of pemetrexed comprises head space oxygen less than 5%, dissolved oxygen less than 2 ppm and individual impurity level less than 0.2%.
    Type: Grant
    Filed: December 18, 2020
    Date of Patent: October 19, 2021
    Assignee: FTF PHARMA PRIVATE LIMITED
    Inventors: Jayanta Kumar Mandal, Sandip Pareshbhai Mehta
  • Patent number: 11149028
    Abstract: The invention provides methods for treating cancers, such as melanoma and/or metastatic melanoma, using compounds that interact with and/or inhibit cellular proteins lamin A/C, ATP-dependent RNA helicase DDX1 (DDX1), heterogeneous nuclear ribonuclear protein H1/H2 (hnRNP H2), and/or heterogeneous nuclear ribonuclear protein A2/B1 (hnRNP A2/B1). The invention additionally provides a method for identifying compounds active against melanoma cells.
    Type: Grant
    Filed: December 15, 2017
    Date of Patent: October 19, 2021
    Assignees: Nova Southeastern University, Auburn University, Florida Atantic University Board Of Trustees, Torrey Pines Institute for Molecular Studies
    Inventors: Dmitriy Minond, Gregg B. Fields, Marcello Giulianotti
  • Patent number: 11147800
    Abstract: The present invention describes methods and compositions for improving the therapeutic efficacy of therapeutic agents previously limited by suboptimal therapeutic performance by either improving efficacy as monotherapy or reducing side effects. Such methods and compositions are particularly applicable to bisantrene or derivatives, analogs, or prodrugs thereof.
    Type: Grant
    Filed: December 3, 2019
    Date of Patent: October 19, 2021
    Assignee: Race Oncology Ltd.
    Inventors: William J. Garner, Arnie Franklin, John Rothman
  • Patent number: 11141409
    Abstract: A method of preventing or treating an immunological or inflammatory disease or disorder comprising administering a composition including a combination of rapamycin and metformin, wherein the molar ratio of rapamycin to metformin is in the range of about 20:1 to about 1:1; 10:1 to about 4:1; 5:1 to about 3:1; or about 5:1 to about 4:1. The composition may be formulated for oral administration, topical administration, parenteral administration, etc.
    Type: Grant
    Filed: July 16, 2020
    Date of Patent: October 12, 2021
    Assignee: JMM Licensing LLC
    Inventor: Jeffrey M. Melin
  • Patent number: 11135201
    Abstract: The present invention describes methods and compositions for improving the therapeutic efficacy of therapeutic agents previously limited by suboptimal therapeutic performance by either improving efficacy as monotherapy or reducing side effects. Such methods and compositions are particularly applicable to bisantrene or derivatives, analogs, or prodrugs thereof. Such methods and compositions are particularly useful for treatment of malignancies.
    Type: Grant
    Filed: January 30, 2020
    Date of Patent: October 5, 2021
    Assignee: RACE ONCOLOGY LTD.
    Inventors: William J. Garner, Amie Franklin, John Rothman
  • Patent number: 11135221
    Abstract: Provided herein, inter alia, are compositions and methods for generating a immune response in an individual and/or inducing the expression of neoantigens on the surface of abnormal (such as proliferative) cells via promotion of premature termination codon (PTC) read-through and inhibition of nonsense-mediated decay (NMD) of messenger RNAs (mRNAs) bearing PTCs.
    Type: Grant
    Filed: December 23, 2016
    Date of Patent: October 5, 2021
    Assignee: MOONSHOT PHARMA LLC
    Inventor: Angela Christiano
  • Patent number: 11129810
    Abstract: This invention relates to a novel dosage regimen for administration of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-N-cyclopropyl-4-methylbenzamide or a pharmaceutically acceptable derivative thereof, namely in the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD).
    Type: Grant
    Filed: February 18, 2020
    Date of Patent: September 28, 2021
    Assignee: MEREO BIOPHARMA 1 LIMITED
    Inventors: Colin Orford, Cyril Clarke, Colm Farrell, Jacqueline Parkin, Stefan De Buck
  • Patent number: 11124510
    Abstract: Disclosed are alkyl chain modified 1H-imidazoquinoline compounds, derivatives and analogs thereof, as Toll-like receptor-7 and -8 agonists for enhancing immune responses. Also provided are methods of making pharmaceutical compositions containing these compounds. The present disclosure also describes methods of use for the alkyl chain modified 1H-imidazoquinoline compounds, derivatives and analogs thereof, and pharmaceutical compositions containing these compounds for the treatment of disease in a subject.
    Type: Grant
    Filed: March 2, 2020
    Date of Patent: September 21, 2021
    Assignee: DYNAVAX TECHNOLOGIES CORPORATION
    Inventors: Stewart D. Chipman, Radwan Kiwan, Melissa A. Kachura, Robert Coffman
  • Patent number: 11109611
    Abstract: A specific type of digestibility in a companion animal can be improved by adjusting the diet of the animal to increase the amount of a compound which positively or negatively modulates the specific type of digestibility or adjusting the diet of the animal to decrease the amount of a compound which positively or negatively modulates the specific type of digestibility. The specific type of digestibility can be one or more of organic matter digestibility, dry matter digestibility, fiber digestibility, energy digestibility, fat digestibility, or protein digestibility.
    Type: Grant
    Filed: March 11, 2020
    Date of Patent: September 7, 2021
    Assignee: SOCIÉTÉ DES PRODUITS NESTLÉ S. A.
    Inventors: Rondo P Middleton, Brian M Zanghi, Serge Andre Dominique Rezzi, Steven S Hannah
  • Patent number: 11110068
    Abstract: Compositions and pharmaceutical compositions including a dendrimer-resveratrol complex and methods for making and using the compositions are described herein. Methods of treating cancer, cardiovascular disease, cardiac failure, diabetes, Alzheimer's disease, Parkinson's disease and other brain diseases, fatty liver disease, obesity, cataracts, osteoporosis, muscle wasting, sleep disorders, acoustic trauma, inflammatory disease, psoriasis, arthritis, colitis, aging, viral disease, reproductive disease, and skin conditions or disorders including administering a therapeutically effective amount of the compositions to a subject in need are also provided. The compositions may be topically applied to skin or mucous membranes.
    Type: Grant
    Filed: July 25, 2019
    Date of Patent: September 7, 2021
    Assignee: Concordia University
    Inventors: Abhay Singh Chauhan, Eric Andrew Newenhouse, Armin Henry Gerhardt
  • Patent number: 11096924
    Abstract: Disclosed are combination therapies including administration of I-DASH inhibitors and PGE2 antagonists, and the use of such therapies in the treatment of cell proliferative diseases.
    Type: Grant
    Filed: September 7, 2017
    Date of Patent: August 24, 2021
    Assignee: Trustees of Tufts College
    Inventors: William W. Bachovchin, Hung-sen Lai, Wengen Wu
  • Patent number: 11096946
    Abstract: The present invention provides methods for reducing loss of muscle strength, muscle mass, or Type I muscle fibers in an immobilized limb by administering (E)-[4-[3-(4-Fluorophenyl)-3-[4-[3-(morpholin-4-yl)propynyl]phenyl]allyloxy]-2-methyl-phenoxy]acetic acid or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: October 22, 2019
    Date of Patent: August 24, 2021
    Assignee: VTV THERAPEUTICS LLC
    Inventors: Maria Carmen Valcarce Lopez, Eliot Ohlstein
  • Patent number: 11096935
    Abstract: The present invention provides methods of use of hexokinase 2 (HK2)/mitochondria-detaching compounds, including jasmonate derivatives and piperazine derivatives and pharmaceutical compositions including such compounds for inducing immune responses in a subject, including potentiating the immune response to hyperproliferative disorders such as cancer and potentiating the immune response to infectious diseases.
    Type: Grant
    Filed: January 29, 2020
    Date of Patent: August 24, 2021
    Assignee: VIDAC PHARMA LTD
    Inventors: Vered Behar, Oren Menahem Becker, Reut Yosef Hamo, Eyal Dor-On
  • Patent number: 11077091
    Abstract: The present invention relates to stable therapeutic compositions of pharmaceutical grade acids and pH buffering agents. The present invention also is directed to methods of treatment for mitochondrial disorders, metabolic conditions, diabetic conditions, and cardiovascular conditions, by administration of compositions of the present disclosure.
    Type: Grant
    Filed: October 28, 2019
    Date of Patent: August 3, 2021
    Assignee: Reven IP HoldCo LLC
    Inventors: James Ervin, Hendrik J. Van Wyk, Brian D. Denomme, Mariette L. Van Wyk, Peter Pacult, Michael A. Volk
  • Patent number: 11077082
    Abstract: Chemical compositions and methods of synthesis thereof. The compositions disclosed and described herein are directed toward thyroid hormone ?v?3 integrin receptor antagonists conjugated to targets of the norepinephrine transporter (NET) or the catecholamine transporter. The compositions have a dual targeting effect and increased targeting efficiency in the treatment and diagnostic imaging of neuroendocrine tumors.
    Type: Grant
    Filed: April 30, 2019
    Date of Patent: August 3, 2021
    Assignee: NANOPHARMACEUTICALS, LLC
    Inventors: Shaker Mousa, Mehdi Rajabi, Ozlem O. Karakus
  • Patent number: 11071722
    Abstract: The invention relates to methods for treating symptoms of PMS and PMDD including muscle ache, bloating, cramping, acne, tender breasts, bloating, fatigue, difficulty concentrating, diminished impulse control, irritability, anxiety, tension, anger, depression, insomnia and/or rapid fluctuations in mood (mood swings). The method comprises administration of a pharmaceutical composition comprising oxaloacetate, oxaloacetate salts, oxaloacetic acid and/or anhydrous enol-oxaloacetate.
    Type: Grant
    Filed: September 21, 2017
    Date of Patent: July 27, 2021
    Inventor: Alan B. Cash
  • Patent number: 11071739
    Abstract: Stable oral liquid compositions including chlorpromazine or a pharmaceutically acceptable salt or solvate of chlorpromazine, and methods of administering the compositions, are disclosed.
    Type: Grant
    Filed: September 29, 2020
    Date of Patent: July 27, 2021
    Assignee: GENUS LIFESCIENCES INC.
    Inventors: Vaishnavi Parikh, Suhas Gumaste